ATE212348T1 - Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente - Google Patents

Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente

Info

Publication number: ATE212348T1
Authority: AT; Austria
Prior art keywords: hydrogen; galanthamin; medications; derivatives; production
Prior art date: 1993-10-15

Application number

AT94115959T

Other languages

English (en)

Inventor

Raymond W Kosley Jr

Larry Davis

Veronica Taberna

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-10

Publication date

2002-02-15

1994-10-10 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2002-02-15 Application granted granted Critical

2002-02-15 Publication of ATE212348T1 publication Critical patent/ATE212348T1/de

Links

229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
239000001257 hydrogen Substances 0.000 abstract 6
229910052739 hydrogen Inorganic materials 0.000 abstract 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
230000003287 optical effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT94115959T 1993-10-15 1994-10-10 Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente ATE212348T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/137,440 US6323195B1 (en)	1993-10-15	1993-10-15	Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number	Publication Date
ATE212348T1 true ATE212348T1 (de)	2002-02-15

Family

ID=22477446

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94115959T ATE212348T1 (de)	1993-10-15	1994-10-10	Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente

Country Status (23)

Country	Link
US (2)	US6323195B1 (de)
EP (2)	EP1020470A3 (de)
JP (1)	JP2664344B2 (de)
KR (1)	KR0169114B1 (de)
CN (1)	CN1039911C (de)
AT (1)	ATE212348T1 (de)
AU (1)	AU696249B2 (de)
CA (1)	CA2118174C (de)
CZ (1)	CZ287071B6 (de)
DE (1)	DE69429708T2 (de)
DK (1)	DK0653427T3 (de)
EG (1)	EG20472A (de)
ES (1)	ES2171428T3 (de)
FI (1)	FI108723B (de)
IL (1)	IL111274A (de)
NO (1)	NO310415B1 (de)
NZ (1)	NZ264683A (de)
PL (1)	PL177730B1 (de)
PT (1)	PT653427E (de)
RO (1)	RO114133B1 (de)
RU (1)	RU2114850C1 (de)
TW (1)	TW363969B (de)
ZA (1)	ZA948062B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9514821D0 (en) *	1995-07-19	1995-09-20	Sod Conseils Rech Applic	Galanthamine derivatives
AT403803B (de) *	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1738800A (en) *	1998-11-23	2000-06-13	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en)	1998-12-24	2004-08-19	Janssen Pharmaceutica N.V.	Controlled release galantamine composition
EP1150695B1 (de) *	1999-01-11	2007-02-28	Atanas Russinov Djananov	Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
US8603546B2 (en) *	1999-01-11	2013-12-10	Herbaceuticals Inc.	Herbal supplement for increased muscle strength and endurance for athletes
ATE254928T1 (de) *	1999-03-31	2003-12-15	Eisai Co Ltd	Stabilisierte zusammensetzung mit nootropen wirkstoffen
EP1237539B1 (de) *	1999-10-26	2005-10-19	Janssen Pharmaceutica N.V.	Orale lösung enthaltend galanthamine und ein süssungsmittel
JP2003516947A (ja)	1999-12-10	2003-05-20	デイビス、ボニー	ニコチン様物質受容体のモジュレーターとしてのガランタミンおよびリコラミンの類似物
NZ516302A (en)	2000-03-31	2004-02-27	Sanochemia Pharmazeutika Ag	Novel derivatives and analogues of galanthamin
US20030162770A1 (en) *	2002-02-22	2003-08-28	Davis Bonnie M.	Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
US20050142193A1 (en) *	2003-12-31	2005-06-30	Lijuan Tang	Galantamine formulations
US20050191349A1 (en) *	2003-12-31	2005-09-01	Garth Boehm	Galantamine formulations
EP1779867A4 (de) *	2004-07-01	2009-12-02	Eisai R&D Man Co Ltd	Mittel zur förderung der nervenreveneration
ATE478659T1 (de) *	2005-05-13	2010-09-15	Alza Corp	Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
US20080188510A1 (en) *	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
DE602006015338D1 (de) *	2005-09-22	2010-08-19	Galantos Pharma Gmbh	Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en)	2005-09-22	2009-10-08	Galantos Pharma Gmbh	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (de)	2005-09-22	2007-04-25	Galantos Pharma GmbH	Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
WO2007035941A2 (en) *	2005-09-23	2007-03-29	Alza Corporation	Transdermal galantamine delivery system
CA2721007C (en)	2008-04-14	2014-04-29	Galantos Pharma Gmbh	Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
US20120184532A1 (en) *	2009-07-23	2012-07-19	Shire Llc	Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (de)	2018-09-28	2020-04-01	Université de Caen Normandie	Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten
CN113292420A (zh) *	2021-05-27	2021-08-24	神隆医药（常熟）有限公司	加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法
US12551491B1 (en) *	2025-07-23	2026-02-17	Alpha Cognition Inc.	Dosage regimens for benzgalantamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL122665B1 (en)	1978-11-21	1982-08-31	Edinen Zentar Chim	Process for preparing novel dienones of narvedine type and their derivatives
US4751306A (en) *	1985-09-09	1988-06-14	E. I. Du Pont De Nemours And Company	Imide intermediates for the preparation of analgesic and/or antagonist octahydrobenzofuroisoquinolines
US4663318A (en)	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
EP0363415B1 (de) *	1987-05-04	2008-10-15	Davis, Bonnie	Mittel zur behandlung der alzheimer-krankheit
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
NL8800350A (nl)	1988-02-12	1989-09-01	Stichting Biomedical Research	Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
CA1320486C (en) *	1988-06-01	1993-07-20	John J. Lafferty	.alpha. -adrenergic receptor antagonists
WO1992020327A1 (en)	1991-05-14	1992-11-26	Ernir Snorrason	Treatment of fatigue syndrome with cholinesterase inhibitors
US5153193A (en)	1991-10-01	1992-10-06	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) *	1991-10-01	1993-07-27	Hoechst-Roussel Pharmaceuticals Incorporated	Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

1993
- 1993-10-15 US US08/137,440 patent/US6323195B1/en not_active Expired - Lifetime
1994
- 1994-10-10 DE DE69429708T patent/DE69429708T2/de not_active Expired - Lifetime
- 1994-10-10 EP EP00107570A patent/EP1020470A3/de not_active Withdrawn
- 1994-10-10 DK DK94115959T patent/DK0653427T3/da active
- 1994-10-10 EP EP94115959A patent/EP0653427B1/de not_active Expired - Lifetime
- 1994-10-10 AT AT94115959T patent/ATE212348T1/de active
- 1994-10-10 ES ES94115959T patent/ES2171428T3/es not_active Expired - Lifetime
- 1994-10-10 PT PT94115959T patent/PT653427E/pt unknown
- 1994-10-13 FI FI944821A patent/FI108723B/fi not_active IP Right Cessation
- 1994-10-13 RU RU94036448A patent/RU2114850C1/ru active
- 1994-10-13 EG EG64194A patent/EG20472A/xx active
- 1994-10-13 IL IL11127494A patent/IL111274A/xx not_active IP Right Cessation
- 1994-10-13 NZ NZ264683A patent/NZ264683A/en not_active IP Right Cessation
- 1994-10-14 RO RO94-01669A patent/RO114133B1/ro unknown
- 1994-10-14 NO NO19943893A patent/NO310415B1/no not_active IP Right Cessation
- 1994-10-14 AU AU75814/94A patent/AU696249B2/en not_active Expired
- 1994-10-14 CA CA002118174A patent/CA2118174C/en not_active Expired - Lifetime
- 1994-10-14 CN CN94117060A patent/CN1039911C/zh not_active Expired - Lifetime
- 1994-10-14 KR KR1019940026303A patent/KR0169114B1/ko not_active Expired - Lifetime
- 1994-10-14 PL PL94305456A patent/PL177730B1/pl unknown
- 1994-10-14 CZ CZ19942546A patent/CZ287071B6/cs not_active IP Right Cessation
- 1994-10-14 TW TW083109526A patent/TW363969B/zh not_active IP Right Cessation
- 1994-10-14 ZA ZA948062A patent/ZA948062B/xx unknown
- 1994-10-17 JP JP6250778A patent/JP2664344B2/ja not_active Expired - Fee Related
1995
- 1995-05-22 US US08/445,921 patent/US5777108A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU7581494A (en)	1995-05-04
JPH07188240A (ja)	1995-07-25
RO114133B1 (ro)	1999-01-29
CZ254694A3 (en)	1995-09-13
PL305456A1 (en)	1995-04-18
CA2118174C (en)	2000-01-18
AU696249B2 (en)	1998-09-03
FI108723B (fi)	2002-03-15
DK0653427T3 (da)	2002-04-15
KR0169114B1 (ko)	1999-01-15
TW363969B (en)	1999-07-11
NO310415B1 (no)	2001-07-02
US6323195B1 (en)	2001-11-27
JP2664344B2 (ja)	1997-10-15
DE69429708T2 (de)	2002-08-29
FI944821A0 (fi)	1994-10-13
DE69429708D1 (de)	2002-03-14
RU2114850C1 (ru)	1998-07-10
CZ287071B6 (en)	2000-08-16
EP1020470A3 (de)	2000-07-26
EP1020470A2 (de)	2000-07-19
CN1111245A (zh)	1995-11-08
EG20472A (en)	1999-05-31
CN1039911C (zh)	1998-09-23
ES2171428T3 (es)	2002-09-16
EP0653427B1 (de)	2002-01-23
PT653427E (pt)	2002-06-28
NO943893L (no)	1995-04-18
EP0653427A1 (de)	1995-05-17
IL111274A (en)	2000-11-21
RU94036448A (ru)	1996-09-10
PL177730B1 (pl)	2000-01-31
NO943893D0 (no)	1994-10-14
ZA948062B (en)	1995-06-06
CA2118174A1 (en)	1995-04-16
FI944821L (fi)	1995-04-16
KR950011443A (ko)	1995-05-15
IL111274A0 (en)	1994-12-29
US5777108A (en)	1998-07-07
NZ264683A (en)	1998-03-25

Legal Events

Date	Code	Title	Description
2002-05-15	UEP	Publication of translation of european patent specification
2011-09-15	EEIH	Change in the person of patent owner

Publication	Publication Date	Title
ATE212348T1 (de)	2002-02-15	Galanthamin derivate, ein verfahren zu ihrer herstellung und ihre verwendung als medikamente
DK0659174T3 (da)	1999-09-20	Derivater af valproinsyre og 2-valproensyreamider samt deres anvendelse som antikonvulsive midler
ATE206420T1 (de)	2001-10-15	Methylenoxindolderivate und verfahren zu ihrer herstellung
ATE201687T1 (de)	2001-06-15	Galanthamin-derivat, ein verfahren zu seiner herstellung und seine verwendung als medikament
NO955023D0 (no)	1995-12-12	Piperidinderivater og fremgangsmåte for fremstilling derav
AU3544593A (en)	1993-09-30	New naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
FI951414L (fi)	1995-03-24	Menetelmä epäpuhtaan klavulaanihapon puhdistamiseksi
GR3030798T3 (en)	1999-11-30	2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors.
ATE211474T1 (de)	2002-01-15	Galanthamin derivate, verfahren zu ihrer herstellung und ihre verwendung als medikamente
HU9402218D0 (en)	1994-09-28	Pyridinecarboximidamide compounds, pharmaceutical compositions containing them and process for producing them
FI103046B1 (fi)	1999-04-15	Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
AU626095B2 (en)	1992-07-23	Hydroxyalkane carboxylic acid derivatives, their production and use
AU590690B2 (en)	1989-11-09	Asymmetrical ester derivatives of 1,4-dihydropyridine-3, 5-dicarboxylic acid
HU9503775D0 (en)	1996-02-28	Benzene derivative useful for ischemic diseases
BR9405997A (pt)	1995-12-19	Composições antitumorais e métodos de tratamento
AU7032594A (en)	1995-04-06	Azoxycyanobenzene derivatives
ATE117689T1 (de)	1995-02-15	Verfahren zur herstellung von lactamderivaten.
ATE139767T1 (de)	1996-07-15	Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
MX9604347A (es)	1998-05-31	Derivados del acido 2-(4-pirazoliloxi-pirimidin-5-il) acetico.